Drug Interaction Study Between AZD3480 and Warfarin (DDI)

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Alzheimer's Disease

Treatments: Drug: AZD3480; Drug: Placebo; Drug: Warfarin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00689637

EudraCt nr 2007-004756-37

D3690C00014

Details and patient eligibility

About

The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

Enrollment: 26 estimated patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Provision of signed written informed consent
• Clinically normal physical findings and laboratory values

Exclusion criteria

• Clinically significant illness or clinically relevant trauma within three weeks before the first dose
• History of clinically significant disease
• Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

26 participants in 2 patient groups

1

Experimental group

Description:

AZD3480 + warfarin

Treatment:

Drug: Warfarin

Drug: AZD3480

2

Experimental group

Description:

Placebo+ warfarin

Treatment:

Drug: Warfarin

Drug: Placebo